



UNIVERSITY OF LEEDS

This is a repository copy of *Investigating the effect of supplementation on Clostridioides (Clostridium) difficile spore recovery in two solid agars.*

White Rose Research Online URL for this paper:  
<http://eprints.whiterose.ac.uk/130099/>

Version: Accepted Version

---

**Article:**

Pickering, DS, Vernon, JJ, Freeman, J et al. (2 more authors) (2018) Investigating the effect of supplementation on Clostridioides (Clostridium) difficile spore recovery in two solid agars. *Anaerobe*, 50. pp. 38-43. ISSN 1075-9964

<https://doi.org/10.1016/j.anaerobe.2018.01.010>

---

© 2018 Elsevier Ltd. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International  
<http://creativecommons.org/licenses/by-nc-nd/4.0/>

**Reuse**

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

1 **Investigating the effect of supplementation on Clostridium difficile spore**  
2 **recovery in two solid agars**

3 Pickering DS<sup>1\*</sup>, Vernon JJ<sup>1</sup>, Freeman J<sup>2</sup>, Wilcox MH<sup>1, 2</sup>, Chilton CH<sup>1</sup>

4 1. Healthcare Associated Infections Research Group, Molecular  
5 Gastroenterology, Leeds Institute for Biomedical and Clinical Sciences,  
6 University of Leeds, West Yorkshire, UK.

7 2. Microbiology, Leeds Teaching Hospitals Trust, Leeds, UK.

8 **\*corresponding author**

9 Email; [umdsp@leeds.ac.uk](mailto:umdsp@leeds.ac.uk)

## Abstract

**Background:** A variety of supplemented solid media are used within *Clostridium difficile* research to optimally recover spores. Our study sought to investigate different media and additives, providing a method of optimised *C. difficile* spore recovery. Additionally, due to the results observed in the initial experiments, the inhibitory effects of three amino acids (glycine, L-histidine & L-phenylalanine) on *C. difficile* spore outgrowth were investigated.

**Methods:** Spores of five *C. difficile* strains (PCR ribotypes 001,015,020,027,078) were recovered on two commonly used solid media (BHI & CCEY) supplemented with various concentrations of germinants (taurocholate, glycine & lysozyme). Agar-incorporation minimum inhibitory concentration (MIC) testing was carried out for glycine and taurocholate on vegetative cells and spores of all five strains. Additionally a BHI broth microassay method was utilised to test the growth of *C. difficile* in the presence of increasing concentrations (0,1,2,3,4%) of three amino acids (glycine, L-histidine, L-phenylalanine).

**Results:** CCEY agar alone and BHI supplemented with taurocholate (0.1/1%) provided optimal recovery for *C. difficile* spores. Glycine was inhibitory to spore recovery at higher concentrations, although these varied between the two media used. In agar-incorporated MIC testing, glycine concentrations higher than 2% (20 g/L) were inhibitory to both *C. difficile* spore and vegetative cell growth versus the control (mean absorbance =  $0.33 \pm 0.02$  vs  $0.12 \pm 0.01$ ) ( $P < 0.001$ ). This indicates a potential mechanism whereby glycine interferes with vegetative cell growth. Further microbroth testing provided evidence of inhibition by two amino acids other than glycine, L-histidine and L-phenylalanine.

34 **Conclusions:** We provide two media for optimal recovery of *C. difficile* spores  
35 (CCEY alone and BHI supplemented with 0.1/1% taurocholate). CCEY is preferred  
36 for isolation from faecal samples. For pure cultures, either CCEY or supplemented  
37 BHI agar are appropriate. The inhibitory nature of three amino acids (glycine,L-  
38 histidine,L-phenylalanine) to *C. difficile* vegetative cell proliferation is also highlighted.

39 **Keywords:** lysozyme, germination, spores, MIC, culture media, taurocholate

## 40 1.1 Introduction

41 Clostridium difficile is a Gram-positive anaerobe responsible for C. difficile infection  
42 (CDI). CDI can vary in severity; mild diarrhoea is the most common presentation but  
43 some patients may develop pseudomembranous colitis (1) and subsequent toxic  
44 megacolon, a surgical emergency with a high mortality rate (~30-80%) (2). Although  
45 cases of CDI have declined considerably in the UK, from 55,498 cases in 2007/2008  
46 to 13,361 in 2013/2014 (3), it remains an infection of concern and the subject of  
47 considerable research efforts.

48 Different solid media are used for C. difficile recovery according to particular  
49 requirements. However the design of all C. difficile isolation media must optimise  
50 vegetative outgrowth from C. difficile spores while providing a selective environment  
51 to suppress other bacteria present in the sample. CCEY (Cycloserine-cefoxitin egg  
52 yolk) agar is a selective medium previously shown to be the most sensitive and cost-  
53 efficient medium for isolating C. difficile from stool samples when compared to  
54 Cycloserine-cefoxitin fructose agar (CCFA), ChromID C. difficile and tryptone soy  
55 agar (TSA) with 5% sheep's blood (4). CCEYL (cycloserine-cefoxitin and 5%  
56 lysozyme) is used by the C. difficile Ribotyping Network (CDRN) for the isolation of  
57 C. difficile from faecal samples (5) on the basis of evidence suggesting the increased  
58 recovery of environmental spores treated with lysozyme (6). CCEYL is suitable for  
59 faecal C. difficile isolation due to the antibacterial actions against the normal  
60 microflora of cycloserine-cefoxitine. Brain Heart Infusion (BHI) agar with  
61 incorporation of taurocholate (a primary bile acid) and glycine in combination has  
62 been widely used to recover spores from pure culture. BHI is not suitable for the  
63 isolation of C. difficile from faecal samples; it is non-selective media allowing the  
64 growth of multiple organisms (7). The effect of bile acids on C. difficile spore

65 germination has been recognised since 1983, and these interactions are still the  
66 focus of much research (8-12). Subsequently, Sorg et al have further investigated  
67 glycine and taurocholate as stimulatory cogermnants (11) and have recorded the  
68 inhibitory nature of secondary bile acids on *C. difficile* spore germination (13, 14).  
69 More recently, Buffie et al (2015) have demonstrated the protective effect of *C.*  
70 *scindens* against *C. difficile* (15), due to the conversion of primary to secondary bile  
71 acids by 7 $\alpha$ -hydroxylation. The inhibitory nature of secondary bile acids has  
72 subsequently been supported by in vitro work (16).

73 In summary, this study seeks to optimise the recovery of *C. difficile* spores on solid  
74 media.

## 75 **1.2 Methods**

### 76 **1.2.1 Spore Production**

77 Spores of five PCR ribotypes (RT 001,015,020, 027 & 078) of *C. difficile* were  
78 prepared as previously described (17). Spore stocks were enumerated by serial  
79 dilution in phosphate-buffered saline (PBS) in a 96-well plate and growth of 20 $\mu$ l  
80 aliquots of each dilution on to CCEYL agar.

81 All experiments were carried out in triplicate unless otherwise stated. All spores were  
82 fresh (<30 days old) unless otherwise stated. In all experiments agar plates were  
83 incubated anaerobically at 37 $^{\circ}$ C and counts of colony forming units (CFU) were  
84 carried out at 48 hours post-inoculation. Spore suspensions were vortexed  
85 vigorously and homogenised for 20 seconds prior to use.

### 86 **1.2.2 Recovery of *C. difficile* spores on solid media**

87 A range of *C. difficile* test recovery agars were prepared. BHI and CCEY were used  
88 as the agar bases and prepared according to the manufacturer's instructions with

89 additions as detailed in table 1. Taurocholate and glycine additions were made prior  
90 to autoclaving, but lysozyme was added subsequently.

91 Spore suspensions of the five *C. difficile* PCR ribotypes were serially diluted (10-fold)  
92 in PBS to  $10^{-9}$  and 20 $\mu$ l of each dilution were spread on to a range of solid agar  
93 plates (Table 1).

94

Media	Additional Additives
BHI / CCEY	Nil
BHI / CCEY	5% lysozyme
BHI / CCEY	0.1% taurocholate
BHI / CCEY	1% taurocholate
BHI / CCEY	0.1% taurocholate, 0.4% glycine
BHI / CCEY	1% taurocholate, 0.8% glycine
BHI / CCEY	1% taurocholate, 4% glycine

95 **Table 1. Solid agar plates utilised in *C. difficile* spore recovery experiments.**  
96 **Media types and additives are shown.**

97

### 98 **4.2.32.2.3 Minimum inhibitory concentration (MIC) testing**

99 Glycine and taurocholate were tested both independently and in combination (4:1  
100 ratio glycine:taurocholate) using an agar-incorporation minimum-inhibitory  
101 concentration method, as previously described (18). Briefly, test compounds were  
102 weighed out in doubling concentrations and added to individual aliquots of Wilkins-  
103 Chalgren anaerobe agar or CCEY agar. CCEY agar was supplemented with 2%  
104 lysed, defibrinated horse blood. Both spore and vegetative (1:10 dilution of 24 hour  
105 Schaedler's broth culture) populations of the five *C. difficile* strains were inoculated  
106 ( $\sim 10^4$  cells) on to glycine/taurocholate incorporated agar. Inhibition of growth was  
107 assessed after anaerobic incubation at 37°C for 48 hours, where the lo west

108 concentration at which visible *C. difficile* growth was inhibited was recorded as the  
109 MIC.

110

#### 111 **1.2.4 Broth Microassay of *C. difficile* inhibition by L-amino acids**

112 BHI broths with increasing concentrations (1, 2, 3, 4%) glycine, L-histidine or L-  
113 phenylalanine) were prepared and 180ul aliquots distributed into a 96-well plate.  
114 Twenty microlitres of spore suspension ( $\sim 5 \times 10^5$  CFU/ml concentration) were  
115 aliquoted in to each well at time zero. Five strains of different ribotypes were utilised  
116 (001, 015, 020, 027, 078). Plates were incubated anaerobically at 37°C for 48 hours.  
117 At 0, 24 and 48 hours absorbance readings at 595nm were determined (Tecan  
118 Infinite 200 Pro reader). Reads were carried out at 25°C under 1atm of pressure.  
119 Negative controls were prepared for each concentration, and the absorbance for the  
120 blanks was subtracted from the absorbance of the inoculated wells to determine an  
121 accurate absorbance reading based on growth alone. All wells were prepared in  
122 triplicate.

#### 123 **1.2.5 Data analysis**

124 Statistical analysis was carried out on IBM SPSS Statistics 22. Data normality was  
125 assessed using histograms and Kolmogorov-Smirnov tests. Levene's test was used  
126 for calculating homogeneity of variance. In both experiments, the variance between  
127 groups was significantly different ( $P < 0.001$ ), hence Welch's ANOVA was utilised.  
128 Group means were compared using Welch's ANOVA with Games-Howell multiple  
129 comparisons.  $\bar{x}$  represents the mean spore recovery of all five ribotypes used. All  
130 means are reported with standard error of the mean (SEM). P values  $< 0.05$  were  
131 considered significant,  $< 0.01$  highly significant and  $P < 0.001$  extremely highly  
132 significant.




133

## 134 1.3 Results

### 135 1.3.1 Recovery of *C. difficile* spores on solid media

136 Considerable variation in spore recovery was observed between the solid media  
137 used (Fig 1). In the absence of any additives, spore recovery was on average 1log  
138 CFU/mL greater for CCEY vs BHI (range = 0.1 – 2.4log<sub>10</sub>CFU/ml) and was  
139 significantly different for all but the 078 strain ( $P > 0.05$ ). Greatest spore recovery  
140 was observed for CCEY ( $\bar{x} = 8.2 \pm 0.03\log_{10}\text{CFU/ml}$ ) and taurocholate supplemented  
141 BHI ( $\bar{x} = 8.3 \pm 0.06\log_{10}\text{CFU/ml}$ ). The addition of lysozyme to either media appeared  
142 to have no substantial effect on the recovery of spores (CCEY  $\bar{x} = 8.2 \pm 0.03$  vs  $8.3 \pm$   
143  $0.04\log_{10}\text{CFU/ml}$ , BHI  $\bar{x} = 7.3 \pm 0.18\log_{10}\text{CFU/ml}$  vs  $7.1 \pm 0.20\log_{10}\text{CFU/ml}$ ) ( $P >$   
144  $0.05$ ). Spore recovery increased on average by 1logCFU/mL when BHI was  
145 supplemented with 0.1 or 1% taurocholate (range = 0 – 2.7log<sub>10</sub>CFU/mL), but no  
146 equivalent increase was observed in CCEY. Strain dependent differences were also  
147 evident in regards to this increase, with the 001 strain showing a considerable  
148 increase in recovery in response to taurocholate ( $5.8 \pm 0.13\log_{10}\text{CFU/ml}$  vs  $8.5 \pm$   
149  $0.08\log_{10}\text{CFU/ml}$ ) ( $P < 0.0001$ ), in contrast to the negligible difference in the 078 ( $8.0$   
150  $\pm 0.08\log_{10}\text{CFU/ml}$  vs  $8.0 \pm 0.12\log_{10}\text{CFU/ml}$ ) ( $P > 0.05$ ). When glycine was  
151 incorporated into media alongside taurocholate, it had no substantial effect on spore  
152 recovery at 0.4 or 0.8% in BHI. Whereas recovery decreased by ~3log and  
153 ~6log<sub>10</sub>CFU/mL in CCEY at the same concentrations. The 027 strain appeared to be  
154 recovered to a greater extent at these concentrations than the other strains. At the  
155 inclusion of the 4% glycine concentration, no spore recovery was seen on plates of  
156 either medium



**Figure 1. Mean ( $\pm$  SE) spore recovery (log<sub>10</sub>CFU/ml) of spores of five *C. difficile* strains inoculated on to a variety of solid agars. Spores were serially diluted in PBS to 10<sup>-9</sup> and each dilution spread on to agar plates in triplicate. Plates were read after 48h of anaerobic incubation. TC= taurocholate, GLY= glycine, L = lysozyme, LLOD = lower limit of detection**

### 158 1.3.2 MIC testing

159 The minimum inhibitory concentration of glycine for all five strains was 20g/L (2.0%)

160 (Figure 2). The MIC was equivalent for both spore and vegetative *C. difficile*

161 populations (only spore data shown). The inhibition was observed in glycine alone

162 and in combination with taurocholate. No inhibition was seen in the presence of the

163 highest concentration of taurocholate (10g/L) (data not shown).

164

165

166

167

168

169

170

171


172

173

174

175

176



174 **Figure 2. MIC testing of spores of five *C. difficile* strains against**  
175 **increasing concentrations of glycine (0, 1.5, 2.0 & 2.5%). Growth**  
176 **was substantially inhibited in all strains at a concentration of**  
**2.0%.**

177 **1.3.3 Broth Microassay of *C. difficile* inhibition by L-amino acids**

178 Glycine, L-phenylalanine and L-histidine completely inhibited growth in all five *C.*  
179 *difficile* ribotypes at higher concentrations (3%) (Figure 3). Glycine and L-  
180 phenylalanine appeared to inhibit growth to a lesser extent at lower concentrations (  
181 1% and 2% respectively) compared to L-histidine. At 48 hours, absorbance began to  
182 decrease for all strains (data not shown), indicating transition from stationary phase  
183 growth to sporulation/death phase.




Figure 3. Mean ( $\pm$  SE) growth of five *C. difficile* strains in BHI with increasing concentrations (0, 1, 2, 3, & 4%) of 3 amino acids. Absorbance readings (595nm) shown are at 0 and 24 hours post-spore inoculation. At higher concentrations of amino acids, growth is inhibited.

185

## 186 **1.4 Discussion**

### 187 **CCEY and taurocholate supplemented BHI are comparable for *C. difficile*** 188 **recovery**

189 We used an agar incorporation method to ascertain the optimal method for recovery  
190 of *C. difficile* spores. Two different solid media, CCEY and BHI were used, with  
191 various concentrations of additives (taurocholate, glycine and lysozyme). The  
192 response of the spores to the addition of the germinant taurocholate in our study was  
193 in accordance with the historical literature (9, 11). When taurocholate was added to  
194 BHI, spore recovery increased on average  $\sim 1 \log_{10} \text{CFU/mL}$ . Lower concentrations of  
195 taurocholate were not tested but may be as effective as the 0.1%/1% used in the  
196 current study; 0.05% taurocholate has previously been investigated and found to be  
197 sufficient (19).

198 The addition of the cogerminant glycine at 0.4% did not increase the recovery of *C.*  
199 *difficile* spores further. However, BHI could provide a source of glycine without  
200 additional supplementation, as it is an undefined medium with unknown levels of  
201 amino acids. Therefore additional glycine supplementation may not be necessary.  
202 Taurocholate supplementation yielded no positive effect on spore recovery on  
203 CCEY. This is expected; spore germination may already be optimised in CCEY due  
204 to the presence of cholate, a stimulatory primary bile acid (10).

205 Most strikingly, when glycine supplementation was increased to a higher  
206 concentration (4%), spore recovery was completely inhibited to below the level of  
207 detection ( $1.2 \log_{10} \text{CFU/ml}$ ) on both CCEY and BHI. In CCEY, a linear concentration  
208 dependent reduction in spore recovery was observed in regard to glycine

209 supplementation. Even supplementation at the lowest concentration used in this  
210 study (0.4%) caused a  $\sim 3\log$ CFU/mL drop in spore recovery on CCEY. This is in  
211 contrast to BHI, where the higher concentration of 0.8% glycine provided no  
212 impediment to recovery. BHI and CCEY are likely to contain differing levels of  
213 glycine; however, this cannot be verified as this is not detailed by the manufacturer.  
214 Finally, 5% lysozyme appeared to offer no additional benefit to spore recovery.  
215 Lysozyme has been historically been cited as a non- receptor based germinant (20,  
216 21). Previously, research has shown increased recovery of lysozyme treated *C.*  
217 *difficile* spores from the environment (6).

218 The lack of effect seen in our work may reflect the different context in which  
219 lysozyme is used. In this study, lysozyme has been used to initiate germination in  
220 freshly produced non-stressed spores. Previous work has used lysozyme to recover  
221 spores from surfaces on hospital wards, where spore numbers are likely to be low.  
222 Environmental *C. difficile* spores are likely to be subjected to physical and chemical  
223 stresses such as detergents, UV light, desiccation and heat (6). This may potentially  
224 increase spore dormancy and reduce the rate of germination. It is possible the  
225 action of lysozyme increases germination of these 'stressed' spore populations,  
226 whereas the effect is unlikely to be observed in relatively newly produced spores.  
227 Previous work supports this hypothesis; lysozyme has been found to have no  
228 substantial effect on spore recovery when added to solid agar (19).

229 Our study demonstrates the comparability of some well used media in recovery *C.*  
230 *difficile* spores. CCEY or BHI supplemented with 0.1% taurocholate appear to be the  
231 most effective with the least amount of supplementation. BHI supplemented with  
232 0.1% taurocholate is more cost effective (£0.15/plate) than CCEY (£0.25/plate);  
233 however it should noted these are estimated costs and there are a range of costs

234 dependent on supplier and supplement purity. BHI is also not appropriate for  
235 isolation of *C. difficile* from clinical specimens or mixed cultures due its non-  
236 selectivity(7).

237 **Glycine and two L-amino acids appear to inhibit *C. difficile* vegetative growth**

238 *C. difficile* was inhibited by increasing concentrations of glycine (2%) when grown on  
239 solid media. Both spores (data not shown) and vegetative cell inocula were used,  
240 and the effect observed was comparable in both cases. Both spore outgrowth and  
241 vegetative cell proliferation were inhibited in the presence of high concentrations of  
242 glycine (~2%) with ribotype variance likely due to natural variation. Differences in  
243 germination (22, 23), growth rates (24), sporulation (23, 25), and toxin production  
244 (26) between strains of different ribotypes have frequently been reported. Our  
245 observations indicate that growth resulting from both spore and vegetative inocula  
246 are inhibited by glycine suggesting a mechanism inhibiting the vegetative growth of  
247 *C. difficile*, rather than germination. This is not surprising; glycine has been identified  
248 as a cogerminant for *C. difficile* spores, with recent kinetic data suggesting a  
249 sequential binding of taurocholate and glycine to different receptors (27).

250 The inhibitory nature of glycine has been reported in other bacterial species (28). A  
251 recent study evaluating glycine as a replacement for sodium bicarbonate in dentistry  
252 found lower levels of bacterial colonisation on titanium appliances airbrushed with  
253 glycine (29). Synergism between glycine and penicillin has also been reported in *H.*  
254 *pylori* eradication (30). However, to the best of our knowledge, the glycine-mediated  
255 inhibition has not previously been reported *C. difficile*. It has been established that  
256 glycine could interfere with the formation of the bacterial cell wall, by replacing D-  
257 alanine residues in linking tetrapeptides and affecting downstream subunit cross-  
258 linkage of the developing peptidoglycan cell wall (31). D-amino acid enantiomers (D-



259 threonine, D-valine, D-leucine, D-methionine) have been found to have a similar  
260 effect on several species including *E. coli* (32, 33), following a similar mechanism to  
261 that proposed for glycine. Although D-amino acids are not ubiquitous in nature, they  
262 are increasingly being recognised as important in some bacterial regulatory  
263 processes, for instance in bacterial cell wall reorganisation in response to stress and  
264 biofilm formation (34). However, our study shows inhibition of *C. difficile* vegetative  
265 growth by not just glycine, but two L-amino acids; L-phenylalanine and L-histidine.  
266 Given this discrepancy, it is unclear what the antibacterial mechanism of action is in  
267 *C. difficile*. It is possible that glycine may replace D-alanine in the bacterial cell wall,  
268 interfering with downstream cross-linkage of peptidoglycan by short-peptide chains.  
269 It seems unlikely that L-phenylalanine or L-histidine could do the same. However,  
270 Peltier et al. (2011)(35) recently described the unique nature of the *C. difficile*  
271 peptidoglycan cell wall in addition to the 4- $\rightarrow$ 3 cross links produced by D,D-  
272 transpeptidation in other bacteria, the peptidoglycan of *C. difficile* contains a  
273 predominance of 3- $\rightarrow$ 3 cross links catalysed by L,D-transpeptidation (35). In light of  
274 this amino acid substitutions may be possible.

275 In addition, recent evidence using *Vibrio cholera* and *Bacillus subtilis* has  
276 established that conversion of L-enantiomers to their D-isoforms could serve as a  
277 regulatory mechanism for cell wall remodelling and inhibiting growth in stationary  
278 phase cultures (36). Furthermore, the recent identification of an alanine-racemase in  
279 *C. difficile* that also accommodates serine as a substrate raises the possibility that  
280 other L-amino acids could be converted to their D-isoforms (37). Alternatively, a high  
281 concentration of D-amino acids could signal for vegetative cells to cease  
282 proliferation.

283 Although potential inhibitory mechanisms are described, it is possible that the effect  
284 observed is partly due to the hypertonicity of the solutions. This is likely to account  
285 for a degree of inhibition at higher concentrations of amino acids (3%+), as in the  
286 case of L-histidine. However, if the inhibition observed were solely due to the  
287 hypertonicity of the solutions, one would not necessarily expect differences in  
288 inhibition between the different amino acids utilised; inhibition was observed with 1%  
289 supplementation of L-phenylalanine. In addition, the lowest concentration of glycine  
290 supplementation decreased spore recovery on CCEY solid agar. Hishinuma et al  
291 (1969) also found that the inhibition produced by 2% glycine was reversible upon  
292 addition of L-alanine. Considered together, these data suggest a unique mechanism  
293 of inhibition independent of solution hypertonicity (28).

294 The use of an undefined medium (BHI) is a limitation of the present study since the  
295 composition of amino acids is not known. Therefore, the concentrations stated in our  
296 broth microassay may not be accurate, and other amino acids may be present that  
297 could potentially influence *C. difficile* growth. The inhibitory concentrations obtained  
298 via agar-incorporated and broth microdilution methods were also different, however  
299 MIC discrepancies between broth microdilution and agar-incorporation methods  
300 have previously been reported (38). Despite these limitations, the results  
301 demonstrate a real antibacterial effect.

302 Previous research has highlighted that the majority of protein (90%) is enzymatically  
303 degraded and digested in the small intestines, with a small amount passing the  
304 terminal ileum (39). Converting previously reported values (40), free amino acids and  
305 peptides pass the terminal ileum at 0.2% and 0.7% respectively after ingestion of a  
306 50g meal. These concentrations are below those utilised in the study, although  
307 ingestion of larger amounts of protein could increase free peptide concentrations to

308 therapeutic levels. The feasibility of utilising the described inhibitory effect in an in  
309 vivo setting is therefore unclear.

310 To summarise, we present data supporting the comparability of two commonly used  
311 media in optimising *C. difficile* recovery from prepared spore stocks. We also  
312 highlight the inhibitory nature of some amino acids, including glycine, on the  
313 vegetative growth of *C. difficile*. Future work should focus on the elucidation of a  
314 mechanism for this observed inhibition, and whether other amino acids have this  
315 inhibitory effect.

## 316 **Acknowledgements**

317 The research reported in this manuscript was funded by the University of Leeds as  
318 part of a funded PhD project.

319

- 320 1. Larson, H.E., Price, A.B., Honour, P. and Borriello, S.P. Clostridium difficile and aetiology of  
321 pseudomembranous colitis. *The Lancet*. 1978, **311**(8073), pp.1063-1066.
- 322 2. Sayedy, L., Kothari, D. and Richards, R.J. Toxic megacolon associated Clostridium difficile  
323 colitis. *World journal of gastrointestinal endoscopy*. 2010, **2**(8), pp.293-297.
- 324 3. PHE. *MRSA, MSSA and E. coli bacteraemia and C. difficile infection: annual epidemiological*  
325 *commentary*. Public Health England, July 2015.
- 326 4. Lister, M., Stevenson, E., Heeg, D., Minton, N.P. and Kuehne, S.A. Comparison of culture  
327 based methods for the isolation of Clostridium difficile from stool samples in a research  
328 setting. *Anaerobe*. 2014, **28**, pp.226-229.
- 329 5. Fawley, W.N., Davies, K.A., Morris, T., Parnell, P., Howe, R., Wilcox, M.H. and Grp, C.W.  
330 Enhanced surveillance of Clostridium difficile infection occurring outside hospital, England,  
331 2011 to 2013. *Eurosurveillance*. 2016, **21**(29), pp.48-57.
- 332 6. Wilcox, M.H., Fawley, W.N. and Parnell, P. Value of lysozyme agar incorporation and alkaline  
333 thioglycollate exposure for the environmental recovery of Clostridium difficile. *Journal of*  
334 *Hospital Infection*. 2000, **44**(1), pp.65-69.
- 335 7. Edwards, A.N., Suarez, J.M. and McBride, S.M. Culturing and Maintaining Clostridium difficile  
336 in an Anaerobic Environment. *Jove-Journal of Visualized Experiments*. 2013, (79), p.8.
- 337 8. Giel, J.L., Sorg, J.A., Sonenshein, A.L. and Zhu, J. Metabolism of Bile Salts in Mice Influences  
338 Spore Germination in Clostridium difficile. *Plos One*. 2010, **5**(1), p.7.
- 339 9. Howerton, A., Ramirez, N. and Abel-Santos, E. Mapping Interactions between Germinants  
340 and Clostridium difficile Spores. *Journal of Bacteriology*. 2011, **193**(1), pp.274-282.
- 341 10. Wilson, K.H. Efficiency of various bile-salt preparations for stimulation of Clostridium difficile  
342 spore germination. *Journal of Clinical Microbiology*. 1983, **18**(4), pp.1017-1019.

- 343 11. Sorg, J.A. and Sonenshein, A.L. Bile salts and glycine as cogerminants for *Clostridium difficile*  
344 spores. *Journal of Bacteriology*. 2008, **190**(7), pp.2505-2512.
- 345 12. Francis, M.B., Allen, C.A., Shrestha, R. and Sorg, J.A. Bile Acid Recognition by the *Clostridium*  
346 *difficile* Germinant Receptor, CspC, Is Important for Establishing Infection. *Plos Pathogens*.  
347 2013, **9**(5), p.9.
- 348 13. Sorg, J.A. and Sonenshein, A.L. Inhibiting the Initiation of *Clostridium difficile* Spore  
349 Germination using Analogs of Chenodeoxycholic Acid, a Bile Acid. *Journal of Bacteriology*.  
350 2010, **192**(19), pp.4983-4990.
- 351 14. Sorg, J.A. and Sonenshein, A.L. Chenodeoxycholate Is an Inhibitor of *Clostridium difficile*  
352 Spore Germination. *Journal of Bacteriology*. 2009, **191**(3), pp.1115-1117.
- 353 15. Buffie, C.G., Bucci, V., Stein, R.R., McKenney, P.T., Ling, L., Gobourne, A., No, D., Liu, H.,  
354 Kinnebrew, M., Viale, A., Littmann, E., van den Brink, M.R., Jenq, R.R., Taur, Y., Sander, C.,  
355 Cross, J.R., Toussaint, N.C., Xavier, J.B. and Pamer, E.G. Precision microbiome reconstitution  
356 restores bile acid mediated resistance to *Clostridium difficile*. *Nature*. 2015, **517**(7533),  
357 pp.205-208.
- 358 16. Thanissery, R., Winston, J.A. and Theriot, C.M. Inhibition of spore germination, growth, and  
359 toxin activity of clinically relevant C-difficile strains by gut microbiota derived secondary bile  
360 acids. *Anaerobe*. 2017, **45**, pp.86-100.
- 361 17. Chilton, C.H., Crowther, G.S., Ashwin, H., Longshaw, C.M. and Wilcox, M.H. Association of  
362 Fidaxomicin with *C. difficile* Spores: Effects of Persistence on Subsequent Spore Recovery,  
363 Outgrowth and Toxin Production. *Plos One*. 2016, **11**(8), p.13.
- 364 18. Baines, S.D., O'Connor, R., Freeman, J., Fawley, W.N., Harmanus, C., Mastrantonio, P.,  
365 Kuijper, E.J. and Wilcox, M.H. Emergence of reduced susceptibility to metronidazole in  
366 *Clostridium difficile*. *Journal of Antimicrobial Chemotherapy*. 2008, **62**(5), pp.1046-1052.
- 367 19. Nerandzic, M.M. and Donskey, C.J. Effective and Reduced-Cost Modified Selective Medium  
368 for Isolation of *Clostridium difficile*. *Journal of Clinical Microbiology*. 2009, **47**(2), pp.397-400.
- 369 20. Paredes-Sabja, D., Bond, C., Carman, R.J., Setlow, P. and Sarker, M.R. Germination of spores  
370 of *Clostridium difficile* strains, including isolates from a hospital outbreak of *Clostridium*  
371 *difficile*-associated disease (CDAD). *Microbiology*. 2008, **154**(Pt 8), pp.2241-2250.
- 372 21. Ionesco, H. Initiation of germination from *Clostridium difficile* spores by lysozyme. *Comptes*  
373 *Rendus Hebdomadaires Des Seances De L Academie Des Sciences Serie D*. 1978, **287**(6),  
374 pp.659-661.
- 375 22. Heeg, D., Burns, D.A., Cartman, S.T. and Minton, N.P. Spores of *Clostridium difficile* Clinical  
376 Isolates Display a Diverse Germination Response to Bile Salts. *Plos One*. 2012, **7**(2), p.9.
- 377 23. Carlson, P.E., Kaiser, A.M., McColm, S.A., Bauer, J.M., Young, V.B., Aronoff, D.M. and Hanna,  
378 P.C. Variation in germination of *Clostridium difficile* clinical isolates correlates to disease  
379 severity. *Anaerobe*. 2015, **33**, pp.64-70.
- 380 24. Tschudin-Sutter, S., Braissant, O., Erb, S., Strandén, A., Bonkat, G., Frei, R. and Widmer, A.F.  
381 Growth Patterns of *Clostridium difficile* - Correlations with Strains, Binary Toxin and Disease  
382 Severity: A Prospective Cohort Study. *Plos One*. 2016, **11**(9), p.10.
- 383 25. Akerlund, T., Persson, I., Unemo, M., Noren, T., Svenungsson, B., Wullt, M. and Burman, L.G.  
384 Increased sporulation rate of epidemic *Clostridium difficile* type 027/NAP1. *Journal of Clinical*  
385 *Microbiology*. 2008, **46**(4), pp.1530-1533.
- 386 26. Akerlund, T., Svenungsson, B., Lagergren, A. and Burman, L.G. Correlation of disease severity  
387 with fecal toxin levels in patients with *Clostridium difficile*-associated diarrhea and  
388 distribution of PCR ribotypes and toxin yields in vitro of corresponding isolates. *J Clin*  
389 *Microbiol*. 2006, **44**(2), pp.353-358.
- 390 27. Ramirez, N., Liggins, M. and Abel-Santos, E. Kinetic Evidence for the Presence of Putative  
391 Germination Receptors in *Clostridium difficile* Spores. *Journal of Bacteriology*. 2010, **192**(16),  
392 pp.4215-4222.

- 393 28. Hishinuma, F., Izaki, K. and Takahashi, H. Effects of Glycine and d-Amino Acids on Growth of  
394 Various Microorganisms. *Agricultural and Biological Chemistry*. 1969, **33**(11), pp.1577-1586.
- 395 29. Cochis, A., Fini, M., Carrassi, A., Migliario, M., Visai, L. and Rimondini, L. Effect of air polishing  
396 with glycine powder on titanium abutment surfaces. *Clinical Oral Implants Research*. 2013,  
397 **24**(8), pp.904-909.
- 398 30. Minami, M., Ando, T., Hashikawa, S.N., Torii, K., Hasegawa, T., Israel, D.A., Ina, K., Kusugami,  
399 K., Goto, H. and Ohta, M. Effect of glycine on *Helicobacter pylori* in vitro. *Antimicrob Agents*  
400 *Chemother*. 2004, **48**(10), pp.3782-3788.
- 401 31. Hammes, W., Schleife, K.H. and Kandler, O. Mode of action of glycine on biosynthesis of  
402 peptidoglycan. *Journal of Bacteriology*. 1973, **116**(2), pp.1029-1053.
- 403 32. Trippen, B., Hammes, W.P., Schleifer, K.H. and Kandler, O. Mode of action of D-amino acids  
404 on the biosynthesis of peptidoglycan *Arch Microbiol*. 1976, **109**(3), pp.247-261.
- 405 33. Caparros, M., Pisabarro, A.G. and de Pedro, M.A. Effect of D-amino acids on structure and  
406 synthesis of peptidoglycan in *Escherichia coli*. *J Bacteriol*. 1992, **174**(17), pp.5549-5559.
- 407 34. Cava, F., Lam, H., de Pedro, M.A. and Waldor, M.K. Emerging knowledge of regulatory roles  
408 of d-amino acids in bacteria. *Cellular and Molecular Life Sciences*. 2011, **68**(5), pp.817-831.
- 409 35. Peltier, J., Courtin, P., El Meouche, I., Lemee, L., Chapot-Chartier, M.P. and Pons, J.L.  
410 *Clostridium difficile* Has an Original Peptidoglycan Structure with a High Level of N-  
411 Acetylglucosamine Deacetylation and Mainly 3-3 Cross-links. *Journal of Biological Chemistry*.  
412 2011, **286**(33), pp.29053-29062.
- 413 36. Lam, H., Oh, D.C., Cava, F., Takacs, C.N., Clardy, J., de Pedro, M.A. and Waldor, M.K. D-amino  
414 acids govern stationary phase cell wall remodeling in bacteria. *Science*. 2009, **325**(5947),  
415 pp.1552-1555.
- 416 37. Shrestha, R., Lockless, S.W. and Sorg, J.A. A *Clostridium difficile* alanine racemase affects  
417 spore germination and accommodates serine as a substrate. 2017, **292**(25), pp.10735-  
418 10742.
- 419 38. Haste, C.J., Dale, S.E., Nary, J., Citron, D., Law, J.H., Roe-Carpenter, D.E. and Chesnel, L.  
420 Comparison of *Clostridium difficile* minimum inhibitory concentrations obtained using agar  
421 dilution vs broth microdilution methods. *Anaerobe*. 2017, **44**, pp.73-77.
- 422 39. Chung, Y.C., Kim, Y.S., Shadchehr, A., Garrido, A., Macgregor, I.L. and Slesinger, M.H.  
423 Protein digestion and absorption in human small intestine. *Gastroenterology*. 1979, **76**(6),  
424 pp.1415-1421.
- 425 40. Adibi, S.A. and Mercer, D.W. Protein digestion in human intestine as reflected in luminal,  
426 mucosal, and plasma amino acid concentrations after meals. *Journal of Clinical Investigation*.  
427 1973, **52**(7), pp.1586-1594.